SynCo Bio Partners has signed a contract to manufacture a live biotherapeutic with a Japanese pharmaceutical company.
The undisclosed company’s product is a live biotherapeutic based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development.
In addition, the developed process will then be transferred to SynCo’s Amsterdam facility and scaled-up, prior to GMP manufacture for phase I clinical trials, including fermentation, formulation and aseptic filling.
Pierre Warffemius, CEO at SynCo, said: We are extremely pleased to be working with our first Japanese partner. I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics.